咨询订购

点击这里给我发消息
Welcome to Raystarbio!Focus On Forefront Bioactive Compounds.
Find Your Distributors

Select Your Country or Region

$ USD

You are here:Home-Research Areas-Other Indications-Anemia

Request The Product List ofAnemia Anemia

    Anemia is defined as a low number of red blood cells. In a routine blood test, anemia is reported as a low hemoglobin or hematocrit. Hemoglobin is the main protein in your red blood cells. It carries oxygen, and delivers it throughout your body. If you have anemia, your hemoglobin level will be low too. If it is low enough, your tissues or organs may not get enough oxygen. Symptoms of anemia -- like fatigue or pain -- happen because your organs aren't getting what they need to work the way they should.

血红蛋白

    Anemia has three main causes: blood loss, lack of red blood cell production, and high rates of red blood cell destruction.

Cat. No. Product Name CAS No. Information
GY03894

GBT-440

1446321-46-5

A new potent allosteric effector of sickle cell hemoglobin; increases the affinity of hemoglobin for oxygen and consequently inhibits its polymerization when subjected to hypoxic conditions; orally bioavailable and partitions highly and favorably into the red blood cell with a RBC/plasma ratio of ∼150.

GY06955

Enarodustat

1262132-81-9

Enarodustat is a novel potent, orally active HIF prolyl hydroxylase (PHD) inhibitor with IC50 of 0.22 uM for PHD2; increases EPO release from Hep3B cells with EC50 of 5.7 uM, increases hemoglobin levels in rats.

GY06666

Rivipansel sodium

1189037-60-2

Rivipansel sodium (GMI-1070, PF-06460031) is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively; predominantly inhibits E-selectin-mediated adhesion and dramatically inhibits sRBC-leukocyte interactions, leading to improved microcirculatory blood flow and improved survival; a valuable novel therapeutic intervention for acute sickle cell crises.

GY04221

Molidustat

1154028-82-6

Molidustat (BAY 85-3934) is an orally active small molecule inhibitor of hypoxia inducible factor prolyl hydroxylase (HIF-PH) with IC50 of 480 nM, 280 nM and 450 nM for PHD1, PHD2, and PHD3, respectively; causes dose-dependent production of erythropoietin (EPO) in healthy Wistar rats and cynomolgus monkeys, increases hemoglobin levels and shows effectivity in the treatment of renal anemia in rats with impaired kidney function, resultsin normalization of hypertensive blood pressure in rat model of CKD.

GY06459

Rivipansel

927881-99-0

GMI-1070 (Rivipansel, PF-06460031) is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively; predominantly inhibits E-selectin-mediated adhesion and dramatically inhibits sRBC-leukocyte interactions, leading to improved microcirculatory blood flow and improved survival; a valuable novel therapeutic intervention for acute sickle cell crises.

GY01075

Roxadustat

808118-40-3

Roxadustat (FG4592, FG-4592) is a potent, orally available HIF prolyl hydroxylase (HIF-PHD) with IC50 of 591.4 nM; FG-4592 stimulates erythropoiesis, regulates iron metabolism, and reduces hepcidin, demonstrates potential for treatment of anemia.

GY06096

Vadadustat

1000025-07-9

Vadadustat (PG-1016548, AKB-6548) is a novel, potent, orally active HIF-PH inhibitor in development for the treatment of anemia in both nondialysis-dependent (NDD) and dialysis-dependent CKD; induces endogenous erythropoietin synthesis and enhances iron mobilization.

GY06062

JTZ-951 hydrochloride

1262131-60-1

JTZ-951 hydrochloride(JTZ 951;JTZ951;Enarodustat) is a potent and orally active HIF prolyl hydroxylase (PHD) inhibitor with IC50 of 0.22 uM (PHD2); significantly increases plasma EPO levels in mice without anorectic effects, dose-dependently increases hemoglobin levels in rats, demonstrates potential for treatment of renal anemia.

GY05861

Daprodustat

960539-70-2

Daprodustat (GSK-1278863;GSK 1278863) is a nove, orally active HIF-prolyl hydroxylase (PHD) inhibitor that stimulate endogenous EPO synthesis and induces effective erythropoiesis by non-EPO effects; shows potential for the treatment of anemia associated with chronic kidney disease.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 RayStarBio. All Rights Reserved. Products are only for research use